The latest news for pharma industry insiders.

Syndax describes the drug as the first of its kind.

The news is part of the organization’s goal of demonstrating a commitment to women’s health.

Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for gastric cancers.

The contest focused on telling the stories of how migraines impacted patients’ careers.

Etira’s CEO discusses recent developments in R&D and with the company’s leadership.

As the first major treatment to be approved for schizophrenia in over 30 years, Cobenfy is poised to set the stage for new approaches in treating mental health disorders.

The latest news for pharma industry insiders.

The resubmission for Dupixent includes new data in pediatric patients with chronic spontaneous urticaria.

A look at one biotech’s mission to map the immune system using artificial intelligence—and how its growth as a Big Pharma partner could help unlock the potential of next-generation cancer treatments.

Kebillidi is the first gene therapy to gain FDA approval for the treatment of aromatic L-amino acid decarboxylase deficiency.

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The latest news for pharma industry insiders.

The Jazz Pharmaceutical president and COO discusses her approach to the role and how it plays into the company’s overall goals.

The survey is part of an initiative from GSK to improve these gaps.

The company will also change its NASDAQ ticker to ONC.

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.

Under terms of the collaboration, Merck will lead the development, manufacturing, and commercialization of LM-299, an investigational bispecific antibody.

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

The latest news for pharma industry insiders.

Pleio’s chief experience officer discusses why these platforms are being embraced by the industry.

Why tapping the value generated for the next set of therapies is critical.

Decisions and strategies related to remote work, AI, and DE&I are especially evolving.

Results from the Phase III KOMET trial found that Koselugo demonstrated a statistically significant objective response rate compared to placebo treating plexiform neurofibromas.